{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T22:36:06Z","timestamp":1789425366638,"version":"build-2803163510"},"reference-count":23,"publisher":"European Respiratory Society (ERS)","issue":"5","license":[{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["ERJ Open Res"],"accepted":{"date-parts":[[2026,6,5]]},"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Inhaled corticosteroid (ICS)\/long-acting \u03b2\n                      <jats:sub>2<\/jats:sub>\n                      -agonist (LABA) therapy is important in asthma. The phase 3 VATHOS study (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/\">ClinicalTrials.gov<\/jats:ext-link>\n                      :\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT05202262\">NCT05202262<\/jats:ext-link>\n                      ) assessed the efficacy and safety of budesonide\/formoterol fumarate dihydrate (BFF)\n                      <jats:italic>via<\/jats:italic>\n                      metered-dose inhaler (MDI) using Aerosphere co-suspension technology (BFF\n                      <jats:sub>A<\/jats:sub>\n                      )\n                      <jats:italic>versus<\/jats:italic>\n                      either budesonide (BD)\n                      <jats:italic>via<\/jats:italic>\n                      MDI using Aerosphere or BFF\n                      <jats:italic>via<\/jats:italic>\n                      dry-powder inhaler (BFF\n                      <jats:sub>DPI<\/jats:sub>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Participants (age 12\u201380\u2005years; n=645) with inadequately controlled asthma on medium-dose ICS or ICS\/LABA were randomised 1:2:2:2 to twice-daily BFF 160\/10\u2005\u03bcg (BFF\n                      <jats:sub>A<\/jats:sub>\n                      160), BFF 320\/10\u2005\u03bcg (BFF\n                      <jats:sub>A<\/jats:sub>\n                      320), BD 320\u2005\u03bcg (BD 320) or open-label BFF\n                      <jats:sub>DPI<\/jats:sub>\n                      320\/9\u2005\u03bcg, respectively. End-points included change from baseline in forced expiratory volume in 1\u2005s area under the curve from 0 to 3\u2005h (FEV\n                      <jats:sub>1<\/jats:sub>\n                      AUC\n                      <jats:sub>0\u20133<\/jats:sub>\n                      ) at 24\u2005weeks (primary), and morning pre-dose trough FEV\n                      <jats:sub>1<\/jats:sub>\n                      at 24\u2005weeks, onset of action (day 1 change in FEV\n                      <jats:sub>1<\/jats:sub>\n                      , 5\u2005min post-dose) and severe exacerbation rates (secondary). Adverse events (AEs) were recorded.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      BFF\n                      <jats:sub>A<\/jats:sub>\n                      320 demonstrated superior lung function\n                      <jats:italic>versus<\/jats:italic>\n                      BD 320 at week 24 (mean change from baseline in FEV\n                      <jats:sub>1<\/jats:sub>\n                      AUC\n                      <jats:sub>0\u20133<\/jats:sub>\n                      : 173 (95% CI 112\u2013233)\u2005mL (p&lt;0.0001); trough FEV\n                      <jats:sub>1<\/jats:sub>\n                      : 61 (95% CI 1\u2013120)\u2005mL (p=0.0447); onset of action: 144 (95% CI 110\u2013177)\u2005mL (p&lt;0.0001)). Severe exacerbation rates were similar between BFF\n                      <jats:sub>A<\/jats:sub>\n                      320 and BD 320 (rate ratio 1.02 (95% CI 0.61\u20131.70); p=0.9473). AEs were similar across treatments (BFF\n                      <jats:sub>A<\/jats:sub>\n                      320, 50.3%; BFF\n                      <jats:sub>A<\/jats:sub>\n                      160, 50.0%; BD 320, 38.1%; BFF\n                      <jats:sub>DPI<\/jats:sub>\n                      , 45.7%). BFF\n                      <jats:sub>A<\/jats:sub>\n                      320 showed non-inferiority to BFF\n                      <jats:sub>DPI<\/jats:sub>\n                      in lung function.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      These findings support the use of BFF\n                      <jats:sub>A<\/jats:sub>\n                      320 with co-suspension delivery technology in people with inadequately controlled asthma on medium-dose ICS or ICS\/LABA.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1183\/23120541.01817-2025","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T11:10:14Z","timestamp":1786014614000},"page":"01817-2025","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Budesonide\/formoterol fumarate dihydrate\n                    <i>versus<\/i>\n                    budesonide with a novel suspension technology for uncontrolled asthma: phase 3 VATHOS study"],"prefix":"10.1183","volume":"12","author":[{"given":"David J.","family":"Jackson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8353-2349","authenticated-orcid":false,"given":"Robert A.","family":"Wise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Papi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Njira","family":"Lugogo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5376-8230","authenticated-orcid":false,"given":"Ruchong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Chami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Armengol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami Z.","family":"Daoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Naucl\u00e9r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Bowen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayman","family":"Megally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olami","family":"Sobande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehul","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2026,8,6]]},"reference":[{"key":"2026091403451552000_12.5.01817-2025.1","unstructured":"Global Initiative for Asthma . Global Strategy for Asthma Management and Prevention. 2025. Available from: http:\/\/ginasthma.org\/"},{"key":"2026091403451552000_12.5.01817-2025.2","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/j.jaip.2021.10.011","article-title":"A practical guide to implementing SMART in asthma management","volume":"10","author":"Reddel","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2026091403451552000_12.5.01817-2025.3","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.jaip.2024.01.011","article-title":"The role of ICS-containing rescue therapy versus SABA alone in asthma management today","volume":"12","author":"Krings","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2026091403451552000_12.5.01817-2025.4","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200666170-00006"},{"key":"2026091403451552000_12.5.01817-2025.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1511190"},{"key":"2026091403451552000_12.5.01817-2025.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2007.05.011"},{"key":"2026091403451552000_12.5.01817-2025.7","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.4155\/fmc.11.133","article-title":"Novel cosuspension metered-dose inhalers for the combination therapy of chronic obstructive pulmonary disease and asthma","volume":"3","author":"Lechuga-Ballesteros","year":"2011","journal-title":"Future Med Chem"},{"key":"2026091403451552000_12.5.01817-2025.8","doi-asserted-by":"crossref","first-page":"15015","DOI":"10.1021\/la302281n","article-title":"Cosuspensions of microcrystals and engineered microparticles for uniform and efficient delivery of respiratory therapeutics from pressurized metered dose inhalers","volume":"28","author":"Vehring","year":"2012","journal-title":"Langmuir"},{"key":"2026091403451552000_12.5.01817-2025.9","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.2147\/COPD.S510214","article-title":"In silico lung deposition profiles of three single-inhaler triple therapies in patients with COPD using functional respiratory imaging","volume":"20","author":"Singh","year":"2025","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2026091403451552000_12.5.01817-2025.10","unstructured":"US Food and Drug Administration . Breztri Aerosphere. Highlights of prescribing information. 2022. www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/212122s000lbl.pdf Date last accessed: 9 July 2025."},{"key":"2026091403451552000_12.5.01817-2025.11","unstructured":"AstraZeneca . AstraZeneca announces the completion of the clinical programme to support the transition of Breztri to next-generation propellant with near-zero global warming potential. 2024. www.astrazeneca.com\/media-centre\/press-releases\/2024\/astrazeneca-announces-the-completion-of-the-clinical-programme-to-support-the-transition-of-breztri-to-next-generation-propellant-with-near-zero-global-warming-potential.html Date last accessed: 9 September 2024."},{"key":"2026091403451552000_12.5.01817-2025.12","unstructured":"European Medicines Agency . Trixeo Aerosphere. Summary of product characteristics. 2020. www.ema.europa.eu\/en\/documents\/product-information\/trixeo-aerosphere-epar-product-information_en.pdf Date last accessed: 9 July 2025."},{"key":"2026091403451552000_12.5.01817-2025.13","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.anai.2011.05.024","article-title":"Efficacy of budesonide\/formoterol pressurized metered-dose inhaler versus budesonide pressurized metered-dose inhaler alone in Hispanic adults and adolescents with asthma: a randomized, controlled trial","volume":"107","author":"Zangrilli","year":"2011","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2026091403451552000_12.5.01817-2025.14","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2008.29.3147"},{"key":"2026091403451552000_12.5.01817-2025.15","unstructured":"AstraZeneca Pharmaceuticals LP . Symbicort. Prescribing information. 2017. www.azpicentral.com\/symbicort\/symbicort.pdf Date last accessed: 1 December 2025."},{"key":"2026091403451552000_12.5.01817-2025.16","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-3003.1999.14a06.x"},{"key":"2026091403451552000_12.5.01817-2025.17","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.02.02402001"},{"key":"2026091403451552000_12.5.01817-2025.18","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1513\/pats.200402-003MS","article-title":"Effects of corticosteroids on lung function in asthma and chronic obstructive pulmonary disease","volume":"1","author":"Donohue","year":"2004","journal-title":"Proc Am Thorac Soc"},{"key":"2026091403451552000_12.5.01817-2025.19","first-page":"CD005533","article-title":"Addition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma","volume":"14","author":"Ducharme","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"2026091403451552000_12.5.01817-2025.20","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2019-000534"},{"key":"2026091403451552000_12.5.01817-2025.21","doi-asserted-by":"crossref","first-page":"611","DOI":"10.2147\/JAA.S401445","article-title":"Symptom burden, health status, and productivity in patients with uncontrolled and controlled severe asthma in NOVELTY","volume":"16","author":"Ding","year":"2023","journal-title":"J Asthma Allergy"},{"key":"2026091403451552000_12.5.01817-2025.22","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jaci.2021.01.007","article-title":"Extrafine triple therapy and asthma exacerbation seasonality: TRIMARAN and TRIGGER post hoc analyses","volume":"148","author":"Papi","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"2026091403451552000_12.5.01817-2025.23","doi-asserted-by":"publisher","DOI":"10.7326\/M22-1460"}],"container-title":["ERJ Open Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/23120541.01817-2025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T10:45:27Z","timestamp":1789382727000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/23120541.01817-2025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":23,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,9,14]]},"published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1183\/23120541.01817-2025"],"URL":"https:\/\/doi.org\/10.1183\/23120541.01817-2025","relation":{},"ISSN":["2312-0541"],"issn-type":[{"value":"2312-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,6]]}}}